# ALPINE IMMUNE SCIENCES, INC.

ALPINE IMMUNE SCIENCES, INC. is a company headquartered in Seattle, WA, United States.

## Company overview

- **Legal name:** ALPINE IMMUNE SCIENCES, INC.
- **Former names in filing history:** Nivalis Therapeutics, Inc. (2015-02-13 to 2017-07-25); N30 Pharmaceuticals, Inc. (2014-11-25 to 2014-11-25)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Seattle, WA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001626199

## About

ALPINE IMMUNE SCIENCES, INC. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001626199, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2024-03-20, it reported annual revenue of USD 58,876,000; net income of USD -32,184,000; total assets of USD 379,852,000 for the fiscal period ended 2023-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2023 (period ended 2023-12-31)

- **Revenue:** $58.9M (USD 58,876,000)
- **Net income:** -$32.2M (USD -32,184,000)
- **Total assets:** $379.9M (USD 379,852,000)
- **Cash and equivalents:** $43.9M (USD 43,921,000)
- **Operating cash flow:** -$79.0M (USD -79,012,000)

### FY2022 (period ended 2022-12-31)

- **Revenue:** $30.1M (USD 30,064,000)
- **Net income:** -$57.8M (USD -57,762,000)
- **Total assets:** $286.7M (USD 286,686,000)
- **Cash and equivalents:** $13.4M (USD 13,376,000)
- **Operating cash flow:** -$43.8M (USD -43,754,000)

### FY2021 (period ended 2021-12-31)

- **Revenue:** $23.4M (USD 23,443,000)
- **Net income:** -$50.3M (USD -50,333,000)
- **Total assets:** $255.9M (USD 255,900,000)
- **Cash and equivalents:** $67.9M (USD 67,907,000)
- **Operating cash flow:** -$15.2M (USD -15,248,000)

### FY2020 (period ended 2020-12-31)

- **Revenue:** $9.3M (USD 9,335,000)
- **Net income:** -$27.9M (USD -27,940,000)
- **Total assets:** $144.1M (USD 144,090,000)
- **Cash and equivalents:** $35.0M (USD 34,959,000)
- **Operating cash flow:** $30.1M (USD 30,084,000)

## Recent SEC filings

- Form 8-K — filed 2024-05-20 — period 2024-05-17 — 8-K
- Form 10-Q — filed 2024-05-09 — period 2024-03-31 — 10-Q
- Form 8-K — filed 2024-05-09 — period 2024-05-09 — 8-K
- Form 10-K/A — filed 2024-04-26 — period 2023-12-31 — 10-K/A
- Form 8-K — filed 2024-04-10 — period 2024-04-10 — 8-K
- Form 8-K — filed 2024-04-05 — period 2024-04-03 — 8-K
- Form 10-K — filed 2024-03-20 — period 2023-12-31 — 10-K
- Form 8-K — filed 2024-03-18 — period 2024-03-18 — 8-K
- Form 8-K — filed 2024-02-07 — period 2024-02-02 — 8-K
- Form SC 13G — filed 2024-02-02
- Form 8-K — filed 2024-01-05 — period 2024-01-04 — 8-K
- Form 8-K — filed 2023-12-21 — period 2023-12-20 — 8-K

---

Updated: 2026-10-23T20:12:17Z

Canonical page: https://altss.com/profile/alpine-immune-sciences-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology